30 non-small cell lung cancer patients treated by EGFR tyrosin kinase inhibitor (Tarceva/lressa) at The Oncological and Palliative care Departement in Hanoi Medical University hospital from 12/2009 to 07/2013 were enrolled in this study, the results was following: EGFR mutation rate 66,6 percent in which deletion rate in exon 19 and point mutation rate in exon 21 were equal (50 percent); the mutation patient had a very significantly higher response rate as compared to the non-mutation patient 89,5 percent vs 10,5 percent, p 0.0001; no difference of reponse rate between non-smokers and smokers, deletion mutation exon 19 patients and point mutation exon 21 patients, rash was a predictive sign for response and it was the most common side effect while diarrhea was the least one. EGFR tyrosin kinase inhibitors were effective treatment for EGFR mutation non-small cell lung cancer and had a very little side effects.
- Đăng nhập để gửi ý kiến